

## New Insights on Feline Infectious Disease On Demand

Premier Sponsor



Agenda		
Session Duration	Торіс	Presenter(s)
60 minutes	<ul> <li>What's New in FIP – The European Prospective</li> <li>Understand how the FCoV-23 outbreak in Cyprus appears to have been caused, and how devastating it has been, and what we have learned about it since the outbreak started</li> <li>Understand how Therapeutic Drug Monitoring can be used to optimise the dose of GS-441524 to be given to each individual cat with FIP</li> <li>Know how useful serum AGP concentrations is when deciding when it is safe to stop treatment FIP treatment.</li> </ul>	Dr. Danielle Gunn-Moore
60 minutes	<ul> <li>Diagnostics for FIP</li> <li>Understand the strengths and weaknesses of different tests for the diagnosis of FIP</li> <li>Make recommendations on which test is appropriate for a potential case accounting for contextual factors</li> <li>Understand how to obtain a definitive diagnosis of FIP and when this would be needed.</li> </ul>	Dr. Kerry Rolph
60 minutes	<ul> <li>Treatment of FIP in the Remdesivir Era: How, When and Why to Stop</li> <li>Understand the mechanisms of drugs currently showing success for the treatment of FIP</li> <li>Review current FIP treatment protocols</li> <li>Discuss limitations in the protocols used to dates</li> <li>Strategize how to improve future treatment outcomes.</li> </ul>	Dr. Krystle Reagan
60 minutes	<ul> <li>Panel Discussion</li> <li>Analyze current diagnostic protocols for FIP</li> <li>Discuss new research and variant trends in FIP</li> <li>Explore current treatment protocols for FIP.</li> </ul>	Dr. Danielle Gunn-Moore, Dr. Kerry Rolph, Dr. Krystle Reagan Moderator: Kerry Peak



## New Insights on Feline Infectious Disease On Demand

Premier Sponsor



Agenda (cont.)			
Session Duration	Торіс	Presenter(s)	
60 minutes	<ul> <li>Lunch and Learn – Presented by Stokes Pharmacy</li> <li>Compounded FIP Medications: Insights, Efficacy and Best Practices</li> <li>Understand the background and recent availability of compounded GS- 441524 for FIP in the United States.</li> <li>Gain insights into Bova's role in providing FIP treatment and what distinguishes their approach.</li> <li>Compare and contrast GS-441524 to EIDD-1931 or Molnupiravir and learn when to use each treatment option.</li> <li>Recognize the differences among various compounded FIP medications and their implications for treatment.</li> <li>Address common misconceptions about black market drugs vs. legitimate compounded treatments.</li> <li>Answer frequently asked questions to clarify confusion surrounding FIP treatment options.</li> </ul>	Mickey O'Connor	
60 minutes	<ul> <li>Can Bacteria Cause Cancer?</li> <li>Understand the potential role that some bacterial infections may play in neoplastic processes</li> <li>Select appropriate diagnostics for the identification of bacteria in neoplastic diseases</li> <li>Make recommendations on the treatment of infections in neoplastic diseases.</li> </ul>	Dr Kerry Rolph	
60 minutes	<ul> <li>Known and Emerging Cancer-Causing Viruses in cats. Why Should We Care?</li> <li>Articulate the relevance to feline medicine of identifying oncogenic viruses</li> <li>Understand mechanisms used by retroviruses and papillomaviruses to contribute to feline cancers</li> <li>Identify viruses with oncogenic potential in cats and evaluate current evidence of pathogenic roles.</li> </ul>	Dr. John Munday	



## New Insights on Feline Infectious Disease On Demand

Premier Sponsor



Agenda (cont.)				
Session Duration	Торіс	Presenter(s)		
60 minutes	<ul> <li>Panel Discussion</li> <li>Evaluate emerging associations between infectious diseases and cancer</li> <li>Discuss the potential for new diagnostics and treatments in some forms of cancer</li> <li>Consider emerging infections and the potential for neoplastic associations.</li> </ul>	Dr. John Munday Dr. Kerry Rolph Moderator: Kerry Rolph		